Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Adagio Medical Holdings ( (ADGM) ) is now available.
On March 31, 2025, Adagio Medical Holdings announced the appointment of Deborah Kaster as Chief Business Officer. The company reported a significant increase in revenue for the fourth quarter and full year of 2024, driven by the introduction of vCLAS in Europe. Despite the revenue growth, Adagio faced substantial net losses due to impairment and increased expenses. The company is prioritizing its FULCRUM-VT pivotal study, which is crucial for FDA approval of its VT Cryoablation System, and aims to complete patient enrollment by the second half of 2025.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is a medical device company specializing in catheter ablation technologies for treating cardiac arrhythmias. The company focuses on developing and commercializing products using its Ultra-Low Temperature Cryoablation technology, particularly targeting ventricular tachycardia with its vCLAS catheter.
YTD Price Performance: -28.21%
Average Trading Volume: 189,950
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.38M
See more data about ADGM stock on TipRanks’ Stock Analysis page.